Nebivolol Actavis (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Actavis, is a beta blocker presented as a tablet for oral use. It is used to lower high blood pressure in adults and may be prescribed as part of a comprehensive antihypertensive regimen.

GNH USA supplies Nebivolol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic antagonist used in the management of elevated arterial pressure. It helps control blood pressure through vasodilation and reduced cardiac output. - Essential hypertension: lowers systolic and diastolic blood pressure in adult patients. - Isolated systolic hypertension: reduces elevated systolic readings while maintaining heart rate. - Diastolic hypertension: decreases high diastolic pressure to target levels.

Nebivolol may cause a range of adverse reactions, from mild to serious. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness, especially on standing. - Bradycardia: slower than normal heart rate. - Nausea: upset stomach or urge to vomit. - Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Symptomatic hypotension: significant drop in blood pressure causing faintness. - Atrioventricular block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, especially in patients with asthma. - Allergic reactions: rash, itching, or swelling of face and throat. - Liver enzyme elevation: abnormal liver function tests.

Before initiating Nebivolol therapy, clinicians should assess patient history and monitor for specific concerns. - Blood pressure monitoring: check baseline and follow‑up readings to gauge effectiveness. - Cardiac function assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders. - Liver impairment: use caution and consider dose adjustment in severe hepatic disease. - Concomitant beta‑blockers: avoid combining with other β‑blockers to prevent excessive bradycardia. - Discontinuation: do not stop abruptly; taper under medical supervision to avoid rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct light.

Nebivolol can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, quinidine): may increase nebivolol plasma levels. - Other antihypertensives (e.g., ACE inhibitors, diuretics): additive blood‑pressure lowering effect. - Non‑selective beta‑blockers: risk of excessive β‑blockade and bradycardia.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (e.g., verapamil): may enhance negative chronotropic effects. - Anti‑arrhythmic agents (e.g., amiodarone): potential for conduction abnormalities. - Insulin or oral hypoglycemics: nebivolol can mask hypoglycemia symptoms. - NSAIDs: may reduce antihypertensive efficacy. - Antidepressants (e.g., sertraline): monitor for combined central nervous system effects.